

BIOPHARMA CREDIT PLC

(THE "COMPANY")

TRANSACTION IN OWN SHARES

BioPharma Credit PLC announces that today it has purchased the following number of its ordinary shares of US 0.01 each through J.P. Morgan Securities plc into treasury.

Ordinary Shares: BPCR LN
Date of purchase: 19 March 2025
Number of ordinary shares purchased: 1,000,000
Lowest price per share: 0.8900
Highest price per share: 0.8900
Trading venue: JPM - Exchange Trade Report

Ordinary Shares: BPCR LN
Date of purchase: 19 March 2025
Number of ordinary shares purchased: 3,000,000
Lowest price per share: 0.8900
Highest price per share: 0.8900
Trading venue: JPMSI

Ordinary Shares: BPCR LN
Date of purchase: 19 March 2025
Number of ordinary shares purchased: 49,634
Lowest price per share: 0.8800
Highest price per share: 0.8900
Trading venue: LSE

Aggregate volume per date per trading venue: 4,049,634
Weighted average price per day per trading venue: 0.8895

Following the above transaction, the Company holds 227,070,344 of its ordinary shares in treasury and has 1,146,861,723 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,146,861,723. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Samuel Adams

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSVKLFFEXLFBBF